Bristol Financial Statements From 2010 to 2020

<div class='circular--portrait' style='background:#689CFD;color: #ffffff;font-size:4em;padding-top: 25px;;'>BM</div>
BMY -- USA Stock  

Report: 6th of August 2020  

Bristol Myers financial statements provide useful quartarly and yearly information to potential investors in Bristol Myers Squibb about the current and past financial position of the company, as well as its overall management performance and changes in basic fundamentals over time. We have found one hundred seventeen available fundamental signals for Bristol Myers Squibb which can be analyzed and compared to other ratios and to its rivals. Make sure you to validate all of Bristol Myers Squibb prevailing market performance against the performance between 2010 and 2020 to make sure the company can sustain itself down the road. Bristol Myers Total Assets Per Share are fairly stable at the moment as compared to the past year. Bristol Myers reported Total Assets Per Share of 57.73 in 2019. Net Current Assets as percentage of Total Assets is likely to grow to 13.00 in 2020, whereas Net Income Per Employee is likely to drop slightly above 106.8 K in 2020.

Search Fundamental Trends

 
Refresh
Check Bristol Myers financial statements over time to gain insight into the future company performance. Apply historical fundamental analysis to find patterns among financial statement drivers such as Direct Expenses of 6.5 B, Consolidated Income of 3.5 B or Cost of Revenue of 7.3 B, as well as many exotic indicators such as Interest Coverage of 9.25, Long Term Debt to Equity of 0.91 or Calculated Tax Rate of 26.35. This can be a perfect complement to check Bristol Myers Valuation or Volatility. It can also complement various Bristol Myers Technical models. Continue to the analysis of Bristol Myers Correlation with competitors.

  Bristol Myers Revenues

Bristol Myers Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets140.2 B129.9 B52.4 B
Increasing
Slightly volatile
Cash and Equivalents13.3 B12.3 B6.3 B
Increasing
Slightly volatile
InvestmentsB3.8 B4.6 B
Decreasing
Stable
Investments Current2.7 BB1.9 B
Increasing
Slightly volatile
Investments Non Current787.2 M767 M2.6 B
Decreasing
Slightly volatile
Deferred Revenue496 M483.3 M1.4 B
Decreasing
Slightly volatile
Property Plant and Equipment Net6.1 B6.3 B5.1 B
Increasing
Slightly volatile
Inventory4.6 B4.3 B1.9 B
Increasing
Slightly volatile
Tax Assets523.4 M510 M1.8 B
Decreasing
Slightly volatile
Trade and Non Trade Receivables6.7 B7.7 B4.8 B
Increasing
Slightly volatile
Trade and Non Trade Payables2.5 B2.4 B2.2 B
Increasing
Very volatile
Goodwill and Intangible Assets93.3 B86.5 B23.9 B
Increasing
Slightly volatile
Total Liabilities84.4 B78.2 B30.7 B
Increasing
Slightly volatile
Shareholders Equity55.7 B51.6 B21.6 B
Increasing
Slightly volatile
Accumulated Retained Earnings Deficit37 B34.5 B33.1 B
Increasing
Slightly volatile
Accumulated Other Comprehensive Income(1.6 B)(1.5 B)(2.4 B)
Increasing
Slightly volatile
Current Assets24.5 B29.4 B16.6 B
Increasing
Slightly volatile
Assets Non Current108.5 B100.6 B35.1 B
Increasing
Slightly volatile
Current Liabilities15.2 B18.3 B10.3 B
Increasing
Slightly volatile
Liabilities Non Current64.7 B59.9 B19.9 B
Increasing
Slightly volatile
Tax LiabilitiesB6.5 B2.2 B
Increasing
Slightly volatile
Total Debt50.4 B46.7 B14.7 B
Increasing
Slightly volatile
Debt Current3.6 B3.3 B1.2 B
Increasing
Slightly volatile
Debt Non Current46.8 B43.4 B13.5 B
Increasing
Slightly volatile
Shareholders Equity USD55.7 B51.6 B21.6 B
Increasing
Slightly volatile
Cash and Equivalents USD13.3 B12.3 B6.3 B
Increasing
Slightly volatile
Total Debt USD50.4 B46.7 B14.7 B
Increasing
Slightly volatile
Accounts Payable2.6 B2.4 B2.2 B
Decreasing
Very volatile
Receivables8.3 B7.7 BB
Increasing
Slightly volatile
Inventories4.6 B4.3 B1.9 B
Increasing
Slightly volatile

Bristol Myers Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Revenues25.1 B26.1 B20 B
Increasing
Slightly volatile
Cost of Revenue7.3 B8.1 B5.5 B
Increasing
Slightly volatile
Selling General and Administrative Expense4.6 B4.9 B4.9 B
Decreasing
Slightly volatile
Research and Development ExpenseB6.1 B5.1 B
Increasing
Slightly volatile
Operating Expenses12.5 B13.1 B10.1 B
Increasing
Slightly volatile
Income Tax Expense1.5 B1.5 B1.2 B
Increasing
Stable
Net Loss Income from Discontinued Operations(7.2 B)(6.7 B)(7.4 B)
Increasing
Slightly volatile
Consolidated Income3.5 B3.5 B3.9 B
Decreasing
Slightly volatile
Net Income to Non Controlling Interests21.6 M21 M321.6 M
Decreasing
Slightly volatile
Net Income3.3 B3.4 B3.6 B
Decreasing
Stable
Net Income Common Stock3.3 B3.4 B3.6 B
Decreasing
Stable
Weighted Average Shares1.6 B1.6 B1.7 B
Decreasing
Slightly volatile
Weighted Average Shares Diluted1.9 B1.7 B1.7 B
Increasing
Stable
Earning Before Interest and Taxes EBIT4.6 BB4.8 B
Decreasing
Stable
Revenues USD25.1 B26.1 B20 B
Increasing
Slightly volatile
Net Income Common Stock USD3.3 B3.4 B3.6 B
Decreasing
Stable
Earning Before Interest and Taxes USD4.6 BB4.8 B
Decreasing
Stable
Gross Profit17.7 B18.1 B14.5 B
Increasing
Slightly volatile
Operating Income4.5 BB4.4 B
Increasing
Stable
Direct Expenses6.5 B8.1 B5.5 B
Increasing
Slightly volatile

Bristol Myers Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Capital Expenditure(902 M)(836 M)(771.5 M)
Decreasing
Slightly volatile
Net Cash Flow Business Acquisitions and Disposals(9 B)(8.8 B)(2.2 B)
Decreasing
Stable
Net Cash Flow Investment Acquisitions and Disposals(164 M)(152 M)(50 M)
Increasing
Stable
Net Cash Flow from Financing8.2 B7.6 B(777.9 M)
Increasing
Slightly volatile
Issuance Repayment of Debt Securities 19 B17.7 B3.5 B
Increasing
Slightly volatile
Issuance Purchase of Equity Shares(7.5 B)(7.3 B)(1.8 B)
Decreasing
Slightly volatile
Payment of Dividends and Other Cash Distributions (2.9 B)(2.7 B)(2.5 B)
Decreasing
Slightly volatile
Net Cash Flow from Investing(10 B)(9.8 B)(3 B)
Decreasing
Stable
Net Cash Flow from OperationsB8.1 B4.9 B
Increasing
Slightly volatile
Effect of Exchange Rate Changes on Cash (9.2 M)(9 M)(1.6 M)
Decreasing
Stable
Net Cash Flow or Change in Cash and Cash Equivalents6.4 B5.9 B1.3 B
Increasing
Slightly volatile
Share Based Compensation358.2 M441 M232.8 M
Increasing
Slightly volatile
Depreciation Amortization and Accretion1.9 B1.7 B823.6 M
Increasing
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Earnings per Basic Share1.932.022.0588
Decreasing
Stable
Earnings per Diluted Share1.922.012.0478
Decreasing
Stable
Earnings per Basic Share USD1.932.022.0588
Decreasing
Stable
Dividends per Basic Common Share1.681.641.4772
Increasing
Slightly volatile
Return on Average Equity0.170.1370.2333
Decreasing
Slightly volatile
Return on Average Assets0.07260.050.1031
Decreasing
Slightly volatile
Return on Invested Capital0.180.1370.2512
Decreasing
Slightly volatile
Gross Margin0.670.6910.7239
Decreasing
Slightly volatile
Profit Margin0.140.1320.1816
Decreasing
Slightly volatile
EBITDA Margin0.250.2560.2765
Decreasing
Stable
Return on Sales0.20.1890.2392
Decreasing
Stable
Asset Turnover0.440.3770.5388
Decreasing
Slightly volatile
Payout Ratio1.00.8121.0215
Increasing
Stable
Enterprise Value over EBITDA19.314.78420.8872
Increasing
Very volatile
Enterprise Value over EBIT24.4220.025.311
Increasing
Very volatile
Price to Earnings Ratio37.2931.77737.5876
Increasing
Stable
Sales per Share15.1716.04711.9554
Increasing
Slightly volatile
Price to Sales Ratio4.574.04.4682
Increasing
Stable
Price to Book Value2.082.0275.1099
Decreasing
Very volatile
Debt to Equity Ratio1.571.5161.3922
Increasing
Slightly volatile
Dividend Yield0.02690.0260.0307
Decreasing
Slightly volatile
Current Ratio1.541.6041.6174
Decreasing
Slightly volatile
Free Cash Flow per Share3.74.4382.4777
Increasing
Slightly volatile
Book Value per Share34.1731.66913.0144
Increasing
Slightly volatile
Tangible Assets Book Value per Share23.126.69116.5331
Increasing
Slightly volatile
Total Assets Per Share62.2857.727227.7245
Increasing
Slightly volatile
Cash Flow Per Share3.033.58372.739
Increasing
Stable
Return on Investment15.49.878817.4137
Decreasing
Stable
Operating Margin23.8822.616220.9814
Decreasing
Stable
Calculated Tax Rate26.3530.452324.6904
Increasing
Stable
Receivables Turnover5.964.01096.5869
Decreasing
Slightly volatile
Inventory Turnover3.122.94393.6698
Increasing
Very volatile
PPandE Turnover4.134.6364.0317
Increasing
Slightly volatile
Cash and Equivalents Turnover3.872.71544.1819
Decreasing
Stable
Accounts Payable Turnover10.2412.05679.3422
Increasing
Slightly volatile
Accrued Expenses Turnover5.285.37414.3305
Increasing
Very volatile
Interest Coverage9.259.013733.2468
Decreasing
Slightly volatile
Long Term Debt to Equity0.910.84090.5207
Increasing
Slightly volatile
Quick Ratio1.131.26081.1049
Increasing
Stable
Net Current Assets as percentage of Total Assets13.08.503714.5628
Decreasing
Stable
Revenue to Assets0.210.20120.4933
Decreasing
Slightly volatile

Bristol Myers Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Earnings per Basic Share1.932.022.0588
Decreasing
Stable
Earnings per Diluted Share1.922.012.0478
Decreasing
Stable
Earnings before Tax4.6 BB4.8 B
Decreasing
Stable
Earnings Before Interest Taxes and Depreciation Amortization EBITDA5.8 B6.7 B5.6 B
Decreasing
Very volatile
Earnings per Basic Share USD1.932.022.0588
Decreasing
Stable
Earnings Before Interest Taxes and Depreciation Amortization USD5.8 B6.7 B5.6 B
Decreasing
Very volatile
Dividends per Basic Common Share1.681.641.4772
Increasing
Slightly volatile
Market Capitalization102.2 B104.6 B86.7 B
Increasing
Slightly volatile
Enterprise Value100.4 B99.1 B88.5 B
Increasing
Slightly volatile
Invested Capital64.3 B59.6 B26.1 B
Increasing
Slightly volatile
Average Equity22.3 B25.1 B16.4 B
Increasing
Slightly volatile
Average Assets57.5 B69.3 B38.7 B
Increasing
Slightly volatile
Invested Capital Average30.6 B36.3 B21 B
Increasing
Slightly volatile
Tangible Asset Value38.1 B43.5 B27.6 B
Increasing
Slightly volatile
Return on Average Equity0.170.1370.2333
Decreasing
Slightly volatile
Return on Average Assets0.07260.050.1031
Decreasing
Slightly volatile
Free Cash Flow6.1 B7.2 B4.1 B
Increasing
Slightly volatile
Return on Invested Capital0.180.1370.2512
Decreasing
Slightly volatile
Gross Margin0.670.6910.7239
Decreasing
Slightly volatile
Profit Margin0.140.1320.1816
Decreasing
Slightly volatile
EBITDA Margin0.250.2560.2765
Decreasing
Stable
Return on Sales0.20.1890.2392
Decreasing
Stable
Asset Turnover0.440.3770.5388
Decreasing
Slightly volatile
Payout Ratio1.00.8121.0215
Increasing
Stable
Enterprise Value over EBITDA19.314.78420.8872
Increasing
Very volatile
Enterprise Value over EBIT24.4220.025.311
Increasing
Very volatile
Price to Earnings Ratio37.2931.77737.5876
Increasing
Stable
Sales per Share15.1716.04711.9554
Increasing
Slightly volatile
Price to Sales Ratio4.574.04.4682
Increasing
Stable
Price to Book Value2.082.0275.1099
Decreasing
Very volatile
Debt to Equity Ratio1.571.5161.3922
Increasing
Slightly volatile
Dividend Yield0.02690.0260.0307
Decreasing
Slightly volatile
Current Ratio1.541.6041.6174
Decreasing
Slightly volatile
Working Capital9.3 B11.1 B6.3 B
Increasing
Slightly volatile
Free Cash Flow per Share3.74.4382.4777
Increasing
Slightly volatile
Book Value per Share34.1731.66913.0144
Increasing
Slightly volatile
Tangible Assets Book Value per Share23.126.69116.5331
Increasing
Slightly volatile
Total Assets Per Share62.2857.727227.7245
Increasing
Slightly volatile
Cash Flow Per Share3.033.58372.739
Increasing
Stable
Revenue Per Employee774.9 K871.5 K753.2 K
Increasing
Slightly volatile
Net Income Per Employee106.8 K114.6 K109.9 K
Increasing
Stable
Return on Investment15.49.878817.4137
Decreasing
Stable
Operating Margin23.8822.616220.9814
Decreasing
Stable
Calculated Tax Rate26.3530.452324.6904
Increasing
Stable
Receivables Turnover5.964.01096.5869
Decreasing
Slightly volatile
Inventory Turnover3.122.94393.6698
Increasing
Very volatile
PPandE Turnover4.134.6364.0317
Increasing
Slightly volatile
Cash and Equivalents Turnover3.872.71544.1819
Decreasing
Stable
Accounts Payable Turnover10.2412.05679.3422
Increasing
Slightly volatile
Accrued Expenses Turnover5.285.37414.3305
Increasing
Very volatile
Interest Coverage9.259.013733.2468
Decreasing
Slightly volatile
Long Term Debt to Equity0.910.84090.5207
Increasing
Slightly volatile
Quick Ratio1.131.26081.1049
Increasing
Stable
Net Current Assets as percentage of Total Assets13.08.503714.5628
Decreasing
Stable
Revenue to Assets0.210.20120.4933
Decreasing
Slightly volatile

Bristol Fundamental Market Drivers

Short Percent Of Float1.35%
Forward Price Earnings7.83
Shares Short Prior Month34.43M
Average Daily Volume Last 10 Day11.02M
Average Daily Volume In Three Month15.81M
Date Short Interest15th of June 2020
Fifty Day Average59.08
Two Hundred Day Average60.58

Bristol Upcoming Events

Upcoming Quarterly Report6th of August 2020
Next Earnings Report29th of October 2020
Next Fiscal Quarter End30th of June 2020
Next Fiscal Year End4th of February 2021
Last Quarter Report31st of March 2020
Last Earning Announcement30th of June 2019

About Bristol Myers Financial Statement Charts

There are typically three primary documents that fall into the category of financial statements. These documents include Bristol Myers income statement, its balance sheet, and the statement of cash flows. Bristol Myers investors use historical funamental indicators, such as Bristol Myers's revenue or net income, to determine how well the company is positioned to perform in the future. Although Bristol Myers investors may use each financial statement separately, they are all related. The changes in Bristol Myers's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Bristol Myers's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Bristol Myers Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Bristol Myers. Please read more on our technical analysis and fundamental analysis pages.
 2017 2018 2019 2020 (projected)
Receivables5.09 B5.35 B7.68 B8.29 B
Inventories1.17 B1.2 B4.29 B4.63 B

Did you try this?

Run Price Transformation Now

   

Price Transformation

Use Price Transformation models to analyze depth of different equity instruments across global markets
All  Next Launch Module

Bristol Myers Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Bristol Myers and Astrazeneca PLC. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Continue to the analysis of Bristol Myers Correlation with competitors. Please also try Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page